Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
7,444.25
(
0.58%
)
US TECH 100
28,731.60
(
1.56%
)
Dow Jones
49,693.20
(
-0.14%
)
Brent Oil
103.70
(
0.00%
)
Bitcoin
79,818.87
(
0.67%
)
News Focus
News Focus
Post# of 7312
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 843
Posts 122977
Boards Moderated 9
Alias Born 09/05/2002

DewDiligence

Member Level

Re: None

Friday, 02/05/2021 9:23:42 AM

Friday, February 05, 2021 9:23:42 AM

Post# of 7312
USPTO extends Ibrance patent until 3/5/2027—(an additional four years):

https://finance.yahoo.com/news/pfizer-confirms-u-patent-term-114500130.html

Ibrance is currenlty PFE's second-largest-selling drug (after Prevnar-13); in 4Q20, Ibrance had annualized worldwide sales of $5.7B, approximately 2/3 in the US.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Detailed Quote
Recent PFE News
More PFE News